Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity
Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity
About this item
Full title
Author / Creator
Publisher
England: eLife Science Publications, Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: eLife Science Publications, Ltd
Subjects
More information
Scope and Contents
Contents
Salicylate and acetylsalicylic acid are potent and widely used anti-inflammatory drugs. They are thought to exert their therapeutic effects through multiple mechanisms, including the inhibition of cyclo-oxygenases, modulation of NF-κB activity, and direct activation of AMPK. However, the full spectrum of their activities is incompletely understood....
Alternative Titles
Full title
Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_9f8a30634906460dbb5a73bbe60e7f86
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_9f8a30634906460dbb5a73bbe60e7f86
Other Identifiers
ISSN
2050-084X
E-ISSN
2050-084X
DOI
10.7554/eLife.11156
